Trump says Iran war "close to over" amid hopes for more negotiations
BOULDER, Colo. - Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) announced today the U.S. retail launch of its hypochlorous acid-based burn relief hydrogel at CVS and Walmart stores nationwide. The stock rose 6.25% over the past week to $2.55, though shares remain down roughly 30% year-to-date.
The hydrogel is indicated for management of minor burns and skin irritations. The formulation is designed to soothe damaged skin and support natural healing, according to a company press release.
This marks Sonoma’s first large-scale consumer burn relief product. The company has an established presence in professional healthcare settings where its hypochlorous acid-based solutions have been used in wound and burn care protocols. Sonoma launched a diaper rash hydrogel in mass retail in 2025.
The product is being commercialized through a U.S.-based partner that distributes through CVS and Walmart. The company stated this aligns with its strategy to leverage partnerships to expand retail presence while maintaining focus on innovation, regulatory compliance, and manufacturing.
"We are excited to expand further into the consumer over-the-counter market with the introduction of our advanced burn relief hydrogel in leading U.S. retailers," said Amy Trombly, Chief Executive Officer of Sonoma Pharmaceuticals. "This launch builds on the strong foundation established by our prior consumer product success and reflects growing consumer awareness of hypochlorous acid as a safe and effective skincare solution."The expansion comes as the company posted 27% revenue growth to $17.7 million over the last twelve months, with a gross profit margin of 38%. According to InvestingPro analysis, the stock appears undervalued at current levels. The platform offers deeper insights into SNOA’s financial health, including 8 additional ProTips and comprehensive metrics for investors evaluating this micro-cap pharmaceutical play.
Sonoma Pharmaceuticals develops and manufactures stabilized hypochlorous acid products for medical, veterinary, and consumer applications. The company supports distribution partners in 55 countries. Its principal office is in Boulder, Colorado, with manufacturing operations in Guadalajara, Mexico, and European headquarters in Roermond, Netherlands.
In other recent news, Sonoma Pharmaceuticals announced the launch of the Aquanil AD product line, which is based on hypochlorous acid and developed exclusively for Persån & Covey, Inc. This new dermatology product line includes Aquanil AD Repair Mist, Recovery Gel, and Rescue Serum, targeting issues such as irritated skin, scars, and rashes. These products are formulated using Sonoma’s Microcyn technology, aimed at sensitive or reactive skin. Additionally, Sonoma Pharmaceuticals disclosed its annual equity grants to employees, including executive officers and non-employee directors. Each non-employee director received 10,000 options at an exercise price of $3.68 per share. These options are structured to vest in three equal parts over three years. These developments highlight the company’s ongoing efforts in product innovation and employee compensation.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.